GH Research (GHRS) Enterprise Value (2020 - 2026)
GH Research (GHRS) posted quarterly Enterprise Value of -$246.3 million for Q4 2025, down 104.91% year-over-year from $5.0 billion in Q4 2024, and up 1.36% quarter-over-quarter from -$249.7 million in Q3 2025.
GH Research (GHRS) Enterprise Value (2020 - 2026) Analysis & Trends
GH Research's Enterprise Value history runs 6 years deep, the most recent figure standing at -$246.3 million for Q4 2025.
- In Q4 2025, Enterprise Value fell 104.91% year-over-year to -$246.3 million; the TTM figure through Dec 2025 stood at -$246.3 million (down 104.91% YoY), while the FY2025 annual figure was -$246.3 million, down 104.91% from the prior year.
- Enterprise Value for Q4 2025 stood at -$246.3 million, up from -$249.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$120.2 million in Q4 2024, with the low at -$280.7 million in Q3 2021.
- The 5-year median for Enterprise Value is -$206.1 million (2022), against an average of -$200.6 million.
- The sharpest annual moves came in 2021 and 2023: Enterprise Value sank 5535620.0% in 2021, then surged 44.76% in 2023.
- GH Research's Enterprise Value stood at -$276.8 million in 2021, then jumped by 40.04% to -$166.0 million in 2022, then increased by 19.23% to -$134.0 million in 2023, then increased by 10.34% to -$120.2 million in 2024, then tumbled by 104.91% to -$246.3 million in 2025.
- Business Quant data shows GHRS's Enterprise Value at -$246.3 million in Q4 2025, -$249.7 million in Q3 2025, and -$253.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | -345.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -345.10 Mn |
| Dec 31, 2025 | -246.25 Mn |
| Sep 30, 2025 | -249.65 Mn |
| Jun 30, 2025 | -253.87 Mn |
| Mar 31, 2025 | -257.51 Mn |
| Dec 31, 2024 | -120.18 Mn |
| Sep 30, 2024 | -122.58 Mn |
| Jun 30, 2024 | -129.10 Mn |
| Mar 31, 2024 | -128.83 Mn |
| Dec 31, 2023 | -134.04 Mn |
| Sep 30, 2023 | -141.93 Mn |
| Jun 30, 2023 | -151.62 Mn |
| Mar 31, 2023 | -159.14 Mn |
| Dec 31, 2022 | -165.96 Mn |
| Sep 30, 2022 | -256.94 Mn |
| Jun 30, 2022 | -265.38 Mn |
| Mar 31, 2022 | -270.75 Mn |
| Dec 31, 2021 | -276.79 Mn |
| Sep 30, 2021 | -280.75 Mn |
| Dec 31, 2020 | -5,000.00 |